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Abstract
Detection of interactions between treatment effects and patient descriptors in clini-
cal trials is critical for optimizing the drug development process. The increasing volume
of data accumulated in clinical trials provides a unique opportunity to discover new
biomarkers and further the goal of personalized medicine, but it also requires innova-
tive robust biomarker detection methods capable of detecting non-linear, and some-
times weak, signals. We propose a set of novel univariate statistical tests, based on
the theory of random walks, which are able to capture non-linear and non-monotonic
covariate-treatment interactions. We also propose a novel combined test, which lever-
ages the power of all of our proposed univariate tests into a single general-case tool.
We present results for both synthetic trials as well as real-world clinical trials, where
we compare our method with state-of-the-art techniques and demonstrate the utility
and robustness of our approach.
Keywords: Random Walks, Statistical Test, Personalized Medicine, Biomarker Selection,
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1 Introduction
Designing new and efficient therapies is a long and ever more costly process, with less than
ten percent of new treatments entering Phase I finally being approved by the FDA and com-
mercialized [1, 2]. One of the major challenges for the improvement of drug development is
to better understand how drugs interact with patients, particularly for treatments displaying
heterogeneous responses. Therefore, conducting a detailed analysis of clinical trial data is
critical to find subgroups of patients with higher benefit-risk ratio or to understand why a
drug does not work on some sub-population to improve existing therapeutic strategies.
Moreover, understanding the relationships of patient descriptors which compose the most
responsive cross-section of the population is of great importance when planning a Phase III
trial, for salvaging failed trials, or accelerating advances in personalized medicine. This
process of biomarker identification is critical to detect sub-groups within a given indication,
but, as shown recently for immunotherapies, can also provide the basis for pan-indication
drug approval [3].
Identifying these patient subgroups, and understanding the descriptors, or covariates,
which distinguish them, is the domain of subgroup analysis. This field of research has a long
history in clinical biostatistics [4, 5, 6], and requires a very careful and rigorous method-
ological approach [7], both for confirmatory or exploratory analysis, due to multiplicity,
reproducibility, and false detection issues. Furthermore, subgroup analysis has garnered
even more attention recently from the pharmaceutical community with both the advent of
cheap and extensive genomic measurements as well as the dawning of the era of so-called
big-data. Now that incredibly detailed patient characterizations are available, the problem
of subgroup identification has shifted from careful statistical analysis of select covariates, to
data-mining and machine learning approaches. While the number of features is increasing by
several order of magnitudes, the number of patients remains typically the same, which makes
the statistical challenge even more difficult. Therefore, effective clinical trial data analysis
requires highly sensitive tools capable of detecting covariate-response associations from noisy
and weak treatment response measurements, including discontinuous and non-monotonic in-
teractions, without inflating the Type-I error rate. Indeed, false positive detection is a major
caveat in subgroup analysis [7], and controlling Type-I error is a crucial requirement for any
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reliable methodology. These tools can be used as a pre-processing step, pruning out in-
significant covariates which might obfuscate accurate subgroup identification. They can also
enable investigators to rank covariates by significance so as to focus laboratory studies to a
few of the most promising biological pathways.
Many methods have been proposed for the detection of covariate-treatment interaction.
In particular, we note modified outcome regression [8], outcome weighted learning [9], and
change-point detection [10] methods as state-of-the art techniques which are useful in con-
structing baseline comparisons, as we do in this work. We refer the reader to the recent
review of Lipkovich et al. [11], where the authors review various methodologies ranging from
classic statistical approaches to more sophisticated machine learning methods. On the one
hand, well-founded and analytically rich statistical techniques provide rigorous estimates of
Type-I error, but often miss complex, non-linear interactions. On the other hand, machine
learning approaches allow for the detection of these complex, and sometimes non-monotonic,
interactions. However, in general they fail to provide a proper estimate of Type-I error for
the impact of individual covariates; they do not possess the characteristics common to proper
statistical tests. Thus, we note a lack of methods which take the best of both worlds, of-
fering high sensitivity for interactions with complex dependencies, while also providing rich
statistical analysis and a controlled Type-I error rate.
To address this shortfall, we propose a new series of statistical tests, each of which is
designed to detect particular structures in the treatment response signal which are often
observed in actual clinical trial data. The proposed tests are constructed from a cumulative
process on the effect size obtained by ranking patients according to a given covariate. These
processes characterize the complex dependency structure of the covariate-treatment effect.
We introduce several observables which capture various facets of these interactions, going
beyond a simple process maximum estimate, as used in [10]. When possible, we derive
theoretical estimates to compute p-values thresholds characterizing Type-I error, and when
not possible, we propose a Monte-Carlo sampling procedure. We also present a new combined
test which leverages the power of all our proposed individual tests to provide robust detection
of significant covariates, while also providing fine-grained control over the Type-I error rate.
Our novel combined test compares favorably to existing state-of-the-art procedures, serving
as an effective tool for the exploration of clinical trial data. We evaluate our approach on
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both synthetic and real clinical trial datasets. For the purpose of this work, we have also
created a synthetic benchmark that captures many “corner cases”, i.e. parameter regimes
where existing methods reveal their limitations. These benchmarks may prove useful for
other researchers to evaluate their methods.
The paper is organized as follows. In Sec. 2, we present the treatment-response model
and introduce some notations. Next, in Sec. 3, we review the current state-of-the-art in
covariate-response correlation analysis and covariate selection. Subsequently, in Sec. 4.1, we
demonstrate a simple correction based on treatment response correlations which addresses
many variance issues observed in current techniques. Then, in Sec. 4.2, we present our novel
individual cumulative response tests based on null-tests against Brownian motion, each of
which is tailored to different features in the measured treatment response. Finally, in Sec. 4.3
we present an approach to merge these individual cumulative tests into a single combined test
which is able to retain the performance of the individual tests while being robust to a priori
unknown treatment response curves. To validate our approach, we present two numerical
analyses. In our first synthetic analysis, reported in Sec. 5, we report objective results of
significant covariate detection performance over a wide range of different treatment response
models. In our second analysis, reported in Sec. 6, we take three real-world clinical trial
datasets and report the significant variables discovered by our method. Finally, we conclude
in Sec. 7 with a discussion of the applicability of our approach and possible avenues for
future work.
2 Drug response model
Let us now describe the mathematical framework of the drug response model. The drug
response model characterizes the observed outcome of a patient as a function of the patient’s
covariates and the treatment which was administered to the patient. We will assume that
this observed outcome is binary or real-valued measurement, e.g. cell counts or cholesterol
levels.
Let us denote the treatment indicator as T . In the common setting of experimental
treatment versus placebo, T is a binary variable with T = −1 corresponding to the placebo
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and, T = 1 to the experimental treatment. Given a vector of covariates X belonging to a
particular patient, we denote the observed outcome under treatment T = t as as R(t)(X).
A trial dataset consists of N patient records, which are assumed to be drawn i.i.d.
randomly, each of which contains the patient’s covariate vector, the applied treatment, and
the observed outcome, i.e. (Xi, Ti, Ri)1≤i≤N where we define Ri , R(Ti)(Xi) for conciseness.
We are interested in the detection of patient covariates which correlate with the spread
between the experimental treatment and the placebo, or treatment effectiveness
E(X) = R(1)(X)−R(−1)(X). (1)
Such covariates can be helpful in the understanding of the treatment action mechanism
and in the selection of patient subgroups where the treatment is the most efficient.
Of course, the spread is not directly observable in practice, as it would require two
treatments to be carried out on the same patient, so we need special methods capable to
estimate the correlation of interest from indirect measurements.
In the next section, we revise existing approaches that can be used for the detection of
covariate-treatment interactions.
3 Existing approaches
The problem of identifying covariate-treatment interaction is directly related to the sub-
group identification problem and methods developed for one can be often adapted for another.
Many different approaches have been proposed to address these problems, starting from
straightforward application of the standard multivariate regression techniques (with explicit
modelling of the treatment-covariate interactions), to more advanced models such as modified
covariates [8], outcome weighted learning [9] or change point statistics analysis [10]. In [12],
Tian & Tibshirani describe an adaptive index model which can be used for risk stratification
or sub-group selection. Other examples of decision tree based algorithms are model based
recursive partitioning [13], SIDES method based differential effect search [14], virtual twins
method [15], subgroup analysis via recursive partitioning, combined additive and tree based
regression [16] and qualitative interaction trees [17].
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In the following subsection, we describe standard statistical procedures as well as existing
state of the art approaches that can be used to detect features correlated with the treatment
effect.
3.1 Linear Regression Test
One na¨ıve approach for the detection of significant covariates would be to simply apply a
linear regression to the observed response variables and study the magnitude of the regres-
sion coefficients learned for each covariate, using, for instance, the F-test or R2 values. To
construct such a regression, one first defines a linear observational model for the measured
response as a function of the covariate-treatment pair (X,T ),
R = αTX + T · βTX + , (2)
where  is a centered random variable independent w.r.t. (X,T ). The vector of regression
coefficients α describes the global impact of patient covariates on the outcome, irrespective of
the applied treatment. This term is often referred to as the trend of the treatment response,
and does not contain any information on treatment effectiveness. The significant coefficients
the vector β can be used as indicators of covariates which correlate with the treatment effect.
In the univariate context, when we analyse a particular variable Xj, (3) is simplified to a
simple linear regression with only two terms:
R = αTj X
j + T · βTj Xj + . (3)
3.2 Modified Outcome
The problem with the statistical test for the observational model defined in Eq. (3) one must
estimate the coefficients α of the trend term jointly with the coefficients of β. Knowledge of α
does not aid in the detection of covariate/treatment interaction, and it harms the estimation
of β, the true variable of interest, by introducing additional variance.
In the modified outcome approach of [8], the authors propose a simple modification to the
observed response prior to regression which removes the effect of the trend term, allowing for
the direct estimation of the expected treatment effectiveness given a set of patient covariates,
E [E(x)|X = x]. The modification of the outcome, in the case of two treatments, consists of
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a multiplication of the observed response with the treatment indicator to create the modified
outcome, Y , R × T . In [8], it is shown that β can then be estimated by a regression
performed according to the observational model,
Y = βTX + . (4)
Due to the nature of clinical trials, for each draw of X, we have only one observation
of R which is drawn from one of the potential arms of the trial at random (e.g. treatment
or placebo). Thus, the modified outcome variable Y may have a very large variance. In-
deed, even if we assume that the per-treatment responses have small variance, the modified
outcome Y = R× T may then contain multiple distinct tight modes, corresponding to each
realization of the treatment variable.
These modes have the effect of inflating the variance of Y ,
var[Y |X] = E[var[Y |X,T ] |X] + var[E[Y |X,T ] |X]. (5)
Even if var[Y |X,T ] is small for each treatment arm, thus causing the expectation of the
variance to be small as well, the variance of the expectation can be arbitrarily large, especially
if the treatment in question has a very strong global effect or if there is a strong shift in
outcome distribution. We propose one possible approach to counteract this variance inflation
in Sec. 4.1.
3.3 Outcome weighted learning
The outcome weighted learning (OWL) [9] approach was initially proposed for the identifi-
cation of patient sub-groups, but similarly to modified covariates it can be easily adapted
for the detection of covariate treatment interactions. The idea of this approach is based on
the construction of a classifier f(x) for the following weighted classification problem
argmin
f
N∑
i=1
wiL(Ti, f(Xi)),where (6)
L is a classification loss function (hinge loss, for example) and wi are positive weights obtained
from observed outcomes Ri, for example, wi = Ri−mini=1..NRi. It wouldn’t make any sense
to try to predict T from X since by construction, T is generated to be independent of X.
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However, when we introduce weights, the classifier tries to separate above all, treatment and
placebo patients with high outcome values, and it might be possible, if there is a pattern
in patient to treatment response. Interestingly, if we adapt this to the univariate case,
this approach becomes equivalent to modified outcome since basically we interested in a
correlation between T and Xj weighted by R which is nothing else than the correlation
between RT and Xj.
3.4 Discontinuous Treatment Response
Until now, we have discussed the use of linear models for the detection of covariate/treatment
interaction. However, this is a very simple assumption to make about the treatment response.
In some cases, a strong non-linear, discontinuous thresholding effect can be the dominant
feature in the covariate-treatment response curve, as reported by Koziol & Wu in [10] for
the case of erythropoietin treatment (r-HuEPO) for the prevention of post-surgery blood
transfusion. Here the authors observed sharp cutoffs in treatment effectiveness as measured
against baseline hemoglobin levels.
In order to detect responsive patient profiles for r-HuEPO treatment, the authors of
[10] proposed to build a stochastic cumulative process test to detect the change-point in
measured baseline hemoglobin. This univariate test is constructed by building a test around
a cumulative process description of the treatment effectiveness. Specifically, both the placebo
and r-HuEPO treatment response curves were sorted according to the value of the measured
baseline hemoglobin for each patient record. Subsequently, a cumulative sum was taken
for each treatment, and a test was constructed to observe the statistical significance of the
difference between these cumulative sums under a specified threshold of baseline hemoglobin.
To construct the test itself, [10] made the observation that under the null-hypothesis (H0)
of no covariate-treatment interaction, the treatment effectiveness should behave as a random
walk when the scale of the covariate is mapped to [0, 1], as the observed response would, in
this case, be independent of the covariate and its ordering. In the limit of of N → ∞, this
random walk converges to a Brownian motion process.
If we denote this random process under H0 as W , then the detection of statistically
significant treatment effectiveness amounts to the detection of the measured cumulative
process significantly diverging from W . In [10], the authors proposed a statistical test that
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was constructed around the maximum value of the measured cumulative process as compared
to the most probable maximum value according to W . In Sec. 4.2, we will demonstrate a
version of Koziol & Wu’s cumulative test, but within the modified outcome framework, and
we will also present a series of new tests which are also based on the comparison between
cumulative response and random process null-hypotheses.
4 Proposed Approach
Similar to the approach of [10] which we described in Sec. 3.4, we focus on univariate detection
of significant covariates through statistical tests based on a null-hypothesis of random walks.
Since real-world trial data can contain many pathological and idiosyncratic response features,
we go further than [10] by introducing, in Sec. 4.2, a set of statistical tests which are designed
to detect different features in the underlying response signal. Since it is impossible to predict
a priori what the best hypothesis of the trial data response should be, we also propose the
use of a combined statistical test. In this way, we are able to utilize our proposed statistical
tests as feature detectors, whose outputs, taken as a whole, create a robust description of
covariate significance.
Because of the specific structure of the test framework, namely repeated tests on individ-
ual variables under controlled randomization, we are able to do better than simple Bonferoni
correction [18] for combining p-values obtained over multiple tests. We note that the com-
bined test we propose in Sec. 4.3 can be utilized independently of the specific tests we
construct, and can be seen as a general procedure for obtaining robust predictions of covar-
iate significance in the setting where one posses many possible statistical tests but requires
an interpretation of the aggregate results.
First, however, we turn our attention to transformations of the raw response data. As
first shown in the modified outcome approach of [8], such transformations can lead to sig-
nificant improvements in the detection of treatment response. We will show how one such
transformation can both improve the signal-to-noise ratio for significant covariate detection,
and also leads to new significance test for the cumulative process approach.
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4.1 Centered Treatment Response
As discussed earlier in Sec. 3.2, it is possible that the separation of the treatment response
curves can induce high variance in the treatment effectiveness, even when the per-treatment
response variance is small. To counteract this effect, we propose the use of a per-treatment
centering, removing the empirical average of the response conditioned on the treatment
applied. This approach is similar in spirit to that of efficiency augmentation [8]. In the
efficiency augmentation approach, one attempts to reduce estimator variance by removing
the trend E[R|X], while in our approach we remove E[R|T ]. In general, it is possible to
combine both approaches, however, we consider only per-treatment centering since explicit
model fitting of R(X) may represent a significant risk of over-fitting on trials with limited
enrollment, where selecting a trend model a priori may introduce unnecessary bias.
For per-treatment centering, given the set of observed trial data (Xi, Ti, Ri), we modify
the measured response,
R˜i , Ri − E[R | T = Ti], (7)
where E[R | T = Ti] is simply the empirical mean of all observed responses for a given
treatment Ti. Next, for the case of two-arm trials, we apply the same modified outcome
approach of [8] to remove the trend term by taking the difference of the two treatments,
Y˜i , R˜i × Ti. (8)
At first glance, such per-treatment centering would seem to remove the treatment ef-
fectiveness signal. However, we note that we are not interested in the magnitude of the
treatment effectiveness itself, but rather the correlation of the treatment effectiveness with
the covariate of study. This correlation is preserved by the centering, and becomes more
easily detectable as the variance of the outcome terms is reduced.
To help motivate our choice of per-treatment centering, we first demonstrate that per-
treatment centering minimizes the variance of the modified outcome.
Lemma 1. Given a randomized trial with each treatment chosen i.i.d. with non-zero prob-
ability and independently of X, for the set of all possible modified outcomes of the form
Ŷ = T · (R + f(T )), where f(T ) is an arbitrary function of the treatment, the function
f(T ) = −E[R|T ]
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provides the minimum achievable variance,
var[Ŷ ] = E[T 2 · var[R|T ]].
Proof. See Appendix A.1.
Additionally, we can observe that the original modified outcome of Ymod = T · R, as
proposed in [8], will always have a larger variance, except in the case that the per-treatment
responses are already centered.
Lemma 2. Given a randomized two-treatment trial, T ∈ {±1}, whose measured data has
the empirical mean and variance µT and σ
2
T , respectively, where each treatment is chosen
with probability piT , then var[Y˜ ] ≤ var[Ymod], since var[Y˜ ] = γ · var[Ymod] where 0 ≤ γ ≤ 1.
Proof. See Appendix A.2.
From Lemma 2, we see that, in the case of two treatment trials, the variance reduction
provided by per-treatment response centering becomes more pronounced as the separation
in expected response between the trials increases and the intra-treatment variance decreases.
This shows the corrective effect of centering in correcting for the problem of multi-modal
response distributions, as discussed earlier in Sec. 3.2.
Now that we have established that per-treatment centering is an effective form of variance
reduction for the modified outcome, the question of treatment-response detection remains.
We now investigate the effect of centering on the correlation between the modified response
and treatment.
Lemma 3. The centering R˜ = R−E[R|T ] only alters the correlation between treatment and
outcome for a specified covariate by a constant amount which does not depend on X,
cov[R˜, T |X] = cov[R, T |X] + CR,T .
Proof. See Appendix A.3.
Since covariance between outcome and treatment is modified only by a constant which
does not depend on the covariate X, we see that the correlation conditioned on covariates
is not lost by introducing a per-treatment centering, only translated.
Additionally, we can see that the centered modified outcome removes the effect of global
effects on the covariate-conditioned signal.
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Lemma 4. For E[T ] = 0, centering removes global dependence between the measured outcome
and treatment, cov[R˜, T ] = 0.
Proof. See Appendix A.4.
Corollary 1. Controlling for the ordering of covariates, the partial correlation between the
centered treatment response and the treatment indicator is zero, ρR,T ·X ≥ ρR˜,T ·X = 0.
From Lemma 4, we make the observation that since the global dependency is removed,
then only conditioning on X introduces a dependency between the treatment and centered
response. Without centering, cov[R, T ] = E[T · E[R|T ]]. This leads to Corollary 1, which
demonstrates that when using centered treatment response, all of the dependency between
R and T is entirely mediated by the covariate X. In other words, for centered treatment
response, we see that there remains no explanation of the covariance other than the effect
of the covariate under investigation. This property provides a greater sensitivity when con-
structing significance tests, as we can be assured that the variability being observed in Y˜ is
only due to X.
4.2 Cumulative Tests
As discussed in Sec. 3.4, nonlinearities in the treatment response signal when conditioned
on patient covariates can lead to poor detection of covariate-treatment correlations when
using linear regression fits. Instead, methods such as [10] propose the use of non-linear tests
based on a theory of random walks. We now discuss a set of novel tests for the detection of
significant levels of covariate-treatment interaction according to p-value.
We first introduce the core transformation utilized by all of our proposed significance
tests. Given some modified outcomes Y , centered or not, and a covariate of interest Xj,
a sorting permutation s = [s1, . . . , sN ] is constructed such that X¯
j = [Xjs1 , X
j
s2
, . . . , XjsN ] is
the vector of patient covariate values sorted in ascending order. Here, we assume that the
covariate in question has some interpretation that allows for a meaningful sense of ordering.
However, it is still possible to use this procedure in the case of purely categorical covariates,
as long as the arbitrarily chosen ordering remains consistent when repeated on the same
covariate.
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Subsequently, a cumulative response vector is then calculated as the cumulative sum,
Cji =
i∑
k=1
Ysk . (9)
Rather than constructing tests on the modified outcomes themselves, we evaluate the statis-
tics of the cumulative response process Cj. By using the known statistics of random walks,
we may construct a strong set of priors on the behavior of Cj under the null-hypothesis of
no covariate-treatment interaction,
H0 : Y ⊥ Xj. (10)
Detecting a significant interaction amounts to the detection of Cj diverging significantly
from the bulk where it is most explained by a random process.
Maximum Value Test. We first turn our attention to small adaptation of the original
cumulative maximum value test of [10], generalizing their change-point detection test to the
case of interaction detection. We propose the use of the maximum value test as a baseline
comparison when used in conjunction with the modified outcome of [8].
Specifically, we define the maximum normalized absolute value of the cumulative response
as
M = max
i∈[1,N ]
∣∣∣∣∣ 1√Nσ2N · Cji
∣∣∣∣∣ , (11)
where σ2N is the sample variance taken of the entries of the realized random walk C
j,
σ2N =
1
N − 1
N∑
i=1
(
Cji −
N∑
k=1
Cjk
)2
. (12)
Next, as mentioned earlier in Sec. 3.4, we observe that as N → ∞, according to Donsker’s
theorem [19], the cumulative process under H0 converges to a Weiner process. The distribu-
tion of the extreme values of a Wiener process is well known in the literature [10, 20, 21],
P
[{
max
0≤t≤1
|Wt|
}
> α
]
= 4
∞∑
i=1
(−1)i+1Φ(−(2i− 1)α), (13)
for any α > 0 where Φ is the standard normal cumulative distribution function (CDF). The
final significance test is constructed from (13) by measuring the probability of the observed
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maximum value and comparing it to the probability that the null-hypothesis of the random
walk could have produced such a result. In this case we are assuming that N is large enough
such that the approximation via Weiner process is accurate.
Brownian Bridge Test. In the case of the maximum value test, we define this base-
line using the standard modified outcome. However, we would like to make use of the
per-treatment response centering we propose in Sec. 4.1 in order to aid in the detection of
covariate-treatment correlation. However, by using this per-treatment centering, the cumu-
lative process is no longer well described by Brownian motion. Once the mean is removed,
the cumulative process is pinned to 0 not just at t = 0, but also at the end of the process
t = 1. An example of such a process is shown in Fig. 1.
Specifically, if we construct the cumulative response using the per-treatment centered
response,
C˜ji =
i∑
k=1
Y˜sk (14)
then, by application of Donsker’s theorem [19], C˜j converges to a Brownian bridge process,
Bt, as N →∞ instead of Wiener process. We can observe this convergence by rescaling the
discrete range of patient indices [1, N ] 7→ [0, 1] via the product tN , to find
1√
Nσ2
btNc∑
k=1
(
Y˜sk + (tN − btNc) Y˜sbtNc+1
)
=⇒
N→∞
(Bt)0≤t≤1.
The same transformation can be applied to the maximum absolute value of the process, as
well.
Now, according to Slutsky’s theorem, we can replace σ2 with its empirical estimate,
max
i∈[1,N ]
∣∣∣∣∣ 1√Nσ2N · C˜ji
∣∣∣∣∣ =⇒N→∞ max0≤t≤1 |Bt| , (15)
which shows that the scaled extremal value of the centered process converges in distribution
to the extremal of the Brownian Bridge. Thus, we are able to construct the statistical
significance test against H0 according to the distribution of extreme values of the Brownian
Bridge process.
And the statistical test rejection zone can be computed according to
P
[{
max
0≤t≤1
|Bt|
}
> α
]
= 2
∞∑
i=1
(−1)n−1e−2i2α2 . (16)
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While this extremal value test is a robust statistic for significant covariate detection, there are
many examples of significant treatment-covariate interaction patterns which may be missed
by constructing H0 from a Brownian Bridge process. In the next section, we discuss some
of these shortcomings and demonstrate an extremal test on Brownian Excursion processes
that succeeds where (16) fails.
Brownian Excursion Test. The maximum absolute value is a good statistic for mono-
tonic signals, where the treatment effect monotonically increases or decreases with the value
of the covariate under study. However, when the covariate does not display monotonicity,
then maximum value tests may produce false negatives with respect to covariate significance.
An example of such a case might be a covariate for which the extreme values, low or high,
are correlated with low treatment response, while mid-range values are correlated with high
treatment response. The max value cumulative process approach may fail in this case as a
particular realization in this case may first decrease, rise, and then decrease again without
ever reaching a critical extremal value which would indicate a statistically significant devi-
ation from H0. However, such a process might indeed be judged significant if the origin of
the process were shifted to the beginning of the domain correlated with positive treatment
effect. Thus, a thoroughly general, if cumbersome, approach might be to utilize a max value
cumulative test evaluated from every possible start position.
Specifically, given a centered cumulative process for a specific covariate C˜, consider the
family of circle-shifted processes constructed from it,
C = {(C˜)l | ∀l = 0, 1, . . . , N}, (17)
where
(C˜i)l =
i∑
k=1
Y˜s(k+l) mod N . (18)
Finding the extremal value for all possible shifts is then the solution to the double max-
imization,
max
C˜∈C
max
i∈[1,N ]
∣∣∣C˜i∣∣∣ . (19)
The solution to this maximization over shifts and time can be be equally accomplished by
generalizing the Brownian bridge process to a ring domain and subsequently defining the
“start” of this process to occur at its minimum. Subsequently, finding the extremal of this
15
Figure 1: Example realizations of both the Brownian Bridge process (left) as well as the
Brownian Excursion process, here constructed via circular shift of existing Brownian Bridge
realization (right). Coloring indicates the re-arrangement used to construct the Brownian
Excursion. For both processes, the 95% confidence region for the process is given in grey. In
this case, a Brownian Bridge process well within the confidence interval (≈ [−1.365, 1.365])
constructs a Brownian Excursion process whose maximum leaves the interval (≈ [0, 1.745]).
resultant process would be equivalent to (19). An example of this construction is given in
Fig. 1.
The procedure we have just described is nothing more than finding the extremal value of
a Brownian Excursion,
max
0≤t≤1
BEt = max
0≤t≤1
Bt − min
0≤t≤1
Bt. (20)
The rejection zone can be computed according to
P
[{
max
0≤t≤1
BEt
}
> α
]
= 2
∞∑
i=1
(4i2α2 − 1)e−2i2α2 . (21)
Process Normalization. The overall maximum of a Brownian motion, or a Brownian
bridge, are natural statistics to consider, however they treat the entire interval [0, 1] to be
homogeneous. However, it is much more likely to observe the maximum value at the right
extreme for Brownian motion, or the center for the Brownian bridge. Therefore, even if
there is a signal in the zone of low variance, we compare it to the maximum over the entire
interval and therefore it might easily be overlooked.
This problem can be solved by considering a rejection zone taking into account the chang-
ing variance of the underlying process. In the case of a Brownian motion, such normalization
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means that the rejection zone becomes a square root hull tα, and in the case of a Brownian
bridge, the hull shape is defined by
√
t(1− t).
Algorithm 1 Single Cumulative Test
Input:
X: Set of Patient Covariates
T : Treatment Indicators
R: Measured Outcome (endpoint)
M : Number of Monte-Carlo Simulations
Preprocessing
for i ∈ 1, . . . , N do
Ri ← Ri − E[R|T = Ti]
Ti ← Ti − E[T ]
Yi ← Ri · Ti
H0 Statistics via MC
for k ∈ 1, . . . ,M do
q ← RandomPermute([1, 2, . . . , N])
C ← (∑ni=1 Yqi)1≤n≤N
S[k] ← Test statistics on C
Test on True Data
s← SortPermutation(X)
C ← (∑ni=1 Ysi)1≤n≤N
V ← Test statistics on C
Output:
p-value← 1
M
∑M
k=1 1S[k]>V
Area Tests. Finally, we propose two more tests
based on the total area under the curve (AUC) statis-
tic, the idea behind the use of the entire area is that
even if the maximum value does not reach the criti-
cal threshold, the fact that there are multiple points
where the process approaches the limit may be indica-
tive of a presence of a signal.
The test statistic in this case is computed as
A =
∑
i∈[1,N ]
∣∣∣∣∣ 1√Nσ2N · Cji
∣∣∣∣∣ . (22)
We also consider a modification of this test where we
sum squared values of the cumulative process,
SA =
∑
i∈[1,N ]
(
1√
Nσ2N
· Cji
)2
. (23)
Implementation. Depending on a prior knowledge
about the type of the signal, other tests can be intro-
duced as well. Since it is not always possible to have
a closed form for the statistic distribution, we use a
general numerical framework based on Monte-Carlo
(MC) simulations to compute statistic critical values
[22, 23]. We describe the process for this evaluation
in Alg. 1.
4.3 Combined Test
As mentioned in the previous section, one may prefer different tests depending on the type
of the signal one expects to observe in the data. However, it is not always possible, or
desirable, to choose a particular test a priori. Instead, one might run all tests in parallel to
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see if some signal is detected by at least a single test. This procedure is a classical multiple
test, and thus one needs to use a correction procedure for calculation of the final p-value
in order to ensure that the Type-I error is not inflated. Standard correction procedures,
such as Bonferoni correction [18], may be too severe, obfuscating the detection of significant
covariates in practice. This is especially true in our case due to high correlation between
our proposed significance tests, thus leading to a significant loss in combined test power.
However, as in [24], it is possible to adapt our numeric procedure to run multiple tests
simultaneously without any losses in Type-I or Type-II errors.
Test Name Description
Baselines
MoLin Modified outcome
linear regression test
Max Max of Brownian motion
Proposed
MaxB Max of Brownian bridge
MaxBN Max of Brownian bridge,
normalized via
√
t(1− t)
MaxBE Max of Brownian excursion
MaxBEN Max of Brownian excursion
normalized via
√
t(1− t)
AreaB Area under Brownian
bridge
SAreaB Squared area under Brown-
ian bridge
Table 1: List of statistical tests
for the identification of covariate-
treatment interactions evaluated in
this work.
Specifically, when calculating the combined sig-
nificance test, for each covariate permutation of the
centered treatment response, we compute the list of
metrics defined by each statistical test included in
the combined test, along with their corresponding
p-values. Subsequently, we compare the vector of
observed statistics with samples generated from ran-
dom permutations of the centered treatment response.
Then, of all the p-values for the individual tests in
the combined test, we use the minimum p-value as
the final aggregated statistic. From this minimum,
we define the order on the set of vectors with p-values
and also compute the p-value of the combined test.
We present the pseudo-code for this combined test in
Alg. 2.
In our experiments, we combine MaxB, MaxBN ,
MaxBE, SAreaB, and SAreaB for our final combined
significance test, thus accounting for many possible
signal shapes. Selecting this subset, rather than ap-
plying all possible tests, reduces the computational
burden of running the combined test. In practice, it
is also possible to build a combined test tailored to a priori knowledge about a given dataset,
as long as such a construction is fixed prior to any analysis of the dataset under investigation.
18
4.4 Multi-dose trials Algorithm 2 Combined Test
Input:
X: Set of Patient Covariates
T : Treatment Indicators
R: Measured Outcome (endpoint)
M : Number of Monte-Carlo Simulations
[F1, . . . , FL]: List of L Tests to Combine
Preprocessing
for i ∈ 1, . . . , N do
Ri ← Ri − E[R|T = Ti]
Ti ← Ti − E[T ]
Yi ← Ri · Ti
H0 Statistics via MC
for m ∈ 1, . . . ,M do
q ← RandomPermute([1, 2, . . . , N])
C ← (∑ni=1 Yqi)1≤n≤N
for l ∈ 1, . . . , L do
S[l,m] ← Fl(C)
Distribution of Minimum p-value
for k ∈ 1, . . . ,M do
P [k] ← min
l
1
M
∑M
m=1 1S[l,m]>S[l,k]
Test on True Data
s← SortPermutation(X)
C ← (∑ni=1 Ysi)1≤n≤N
V ← min
l
1
M
∑M
m=1 1S[l,m]>Fl(C)
Output:
Combined p-value← 1
M
∑M
k=1 1P [k]>V
Up to this point, we have considered the case of a clin-
ical trial with only two treatment groups (e.g. placebo
vs. treatment). However, in many cases, such as
Phase II trials, multiple treatment doses are tested
in parallel. In this section, we demonstrate how our
approach may be generalized to the case of multiple
doses trials. The generalization is quite straightfor-
ward: instead of T ∈ {±1} being a binary variable,
we let instead T ∈ T ⊂ R be a real-valued encoding
of different doses. The set T may be a discrete scale
encoding only dose order, or perhaps a more precise
representation of the dosing amount, e.g. log value of
the amount of administered treatment.
As in the binary case, the only important condi-
tion we need to ensure is that E[T ] = 0. As long
as this is true, then we can directly apply the mod-
ified outcome transformation and use the framework
of cumulative processes without any additional mod-
ifications. In essence, in the binary case we focus on
the conditional correlation between R and a centered
binary variable T conditioned on X, and in the multi-
dose case we do the same thing only with T being
simply centered.
5 Synthetic Experiments
In order to evaluate the efficiency of the proposed approach in an objective manner with
known ground-truth, we generate a synthetic dataset of clinical trials. Although these models
do not reflect the full complexity of such data in practice, we consider synthetic models for
two main reasons: (i) to validate the ability of the evaluated statistical tests to accurately
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recover covariates which are known to be significantly correlated with the treatment, and
(ii) to investigate particular cases of linear and non-linear interactions between covariates
and treatment effects, demonstrating the strengths and weaknesses of each test. We list
all of evaluated statistical tests in Table 1. Additionally, we demonstrate how to construct
synthetic datasets for which each of the proposed test will fail, giving insight into the failure
cases for each of the proposed statistical tests. We will also show that the combined test
proposed in Sec. 4.3 provides near best-case accuracy for most of the tested synthetic models.
5.1 Synthetic models
For our experiments, we construct a wide array of synthetic treatment response curves whose
purpose is to simulate the complex behavior observed in real-world clinical trials. Below, we
describe each of the different synthetic models.
We consider three types of synthetic models, in order of increasing complexity, (i) a linear
model, (ii) a set of piecewise-constant models, and (iii) a fully non-linear model.
For all these models, we generate covariates as i.i.d. uniform random variables over [0, 1].
Next, given the full set of patient covariates X, we write the response model in the general
form,
R[T |X] = Wtrend(X) + T ·Winteract(X) + , (24)
where  ∼ N (0,∆) is a noise term with variance ∆, and Wtrend(·) and Winteract(·) are functions
operating across the set of covariates.
Linear Model. The linear model (L) corresponds to the case where Wtrend and Winteraction
are linear functions of the of the first covariate, in this case
Wtrend(X) = W1X
1, (25)
Winteract(X) = W2X
1. (26)
A successful test for L would report X1 as a statistically significant covariate in terms of
treatment interaction, and all other covariates would be rejected.
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(a) L for ∆ = 0.25, W1 = 2, W2 = 1 (b) PC-Int2 for ∆ = 0.25, W1 = 2, W2 = 1
(c) NL for ∆ = 0.25
Figure 2: Example R[T |X] curves of different synthetic models for N = 100.
Piecewise-constant Models. These proposed piecewise-constant (PC) synthetic models
contain either one or two discontinuous jumps, denoted as thresholding and interval effects,
respectively. Such discontinuities are not captured in linear models, however such effects are
ubiquitous throughout biology and medicine.
We introduce four versions of PC models to capture these different configurations. All
choices of Winteraction(X) are simple indicator functions with different supports to capture
both thresholding and interval discontinuities. We present two thresholding models con-
taining a single jump discontinuity, PC-Th1 and PC-Th2, as well as two interval models
containing two jump discontinuities, PC-Int1 and PC-Int2,
Winteract(X) = W21[1/2,1](X
1), (PC-Th1)
Winteract(X) = W21[0,1/8](X
1), (PC-Th2)
Winteract(X) = W21[1/4,3/4](X
1), (PC-Int1)
Winteract(X) = W21[7/16,9/16](X
1). (PC-Int2)
21
Finally, for each of the four different PC models, we use a linear baseline trend ofWtrend(X) =
W1X
1.
Non-linear model. For the non-linear model (NL), we utilize the fourth synthetic sce-
nario reported in Sec. 4 of [9]. Specifically, the covariate-treatment signal is generated
according to
Wtrend(X) = 1 + 2X
1 +X2 + 0.5X3, (27)
Winteract(X) = 1−
(
X1
)3
+ exp{(X3)2 +X5}+ 0.6X6 − (X7 +X8)2 . (28)
We note that covariate X4 is already a decoy covariate in this definition. Additionally,
covariates X7 and X8 are symmetric.
Experimental Parameters. For our experiments, we evaluated the proposed statistical
tests on the given synthetic models over a range of easy and difficult settings. Overall,the
difficulty of the task can be controlled by modifying ∆, the ratio between baseline and
treatment effect (W1/W2), and the number of significant covariates versus total number of
decoy covariates. Specifically, we construct our experiments along these three axes in the
following manner.
• Noise: The variance of the noise term is evaluated over the range
√
∆ ∈ [1, 8].
• W1: The ratio between the scale of the trend term (baseline coefficient) and the
interaction term. Here, we fix W2 = 1 while varying W1 over [1, 5].
• Decoy: Given the fixed number of significant covariates, 1 for L and PC and 7 for NL,
D decoy covariates drawn i.i.d. randomly are added to the dataset. We vary D over
[1, 100].
Performance metrics. Each of the evaluated significance tests are compared based on
their statistical power when their Type-I errors are fixed. Specifically, after generating
synthetic data several times and performing all with a p-value 0.05 significance threshold,
we compare the significance tests by their ability to detect the known significant covariates
in each synthetic model.
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Figure 3: Comparison of individual tests for model PC-Int1 under varying experimental
parameters. Left Comparison over noise standard deviation,
√
∆. Right: Comparison over
the value of the model baseline coefficient W1. The legend remains consistent over both
charts.
Since the test power is a function of many parameters describing various aspects of
signal-to-noise ratio, in our experiments we also trace test sensitivity as a function of the
experimental axes described in the previous section. We then compare the resulting curves
to estimate which test provides the best performance over the tested range. Fig. 3 shows
an example of such curves for different significance tests performed on the PC-Int1 model
under varying noise and baseline strength. As an aggregate measure for overall test perfor-
mance, we compute the area under each curve. In this particular example, MaxBE is the
best performing significance test, as it is capable of detecting the signal more often than
alternative approaches.
5.2 Results
Centering effect. Fig. 4 shows the improvement made by removing the average values
on each group of patients, comparing only the Max tests performed on either a Brownian-
Motion-like process (no centering) or on a Brownian-Bridge-like process (centering). For
visual convenience, the scores are normalized by the maximum value per dataset (column)
such that there is alway a test with the performance score equal to 1 in each simulation
scenario. As expected from our theoretical analysis, we observe that the test with centering
correction (MaxB), in general, provides better significant covariate detection than the test
with no centering correction (Max ).
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Figure 4: Detailed performance comparison between Brownian Motion (un-centered re-
sponse) Max and Brownian Bridge (centered response) MaxB tests over the evaluated
models and experimental parameters.
Main result summary. A global summary of the main results is presented in Fig. 5 for
the cumulative process tests MaxB, MaxBN , MaxBE, MaxBEN , AreaB, SAreaB, the baseline
linear correlation test with modified outcome MoLin, and also for the combined test Comb.
On this chart, each row corresponds to the designated test, while each column corresponds
to a particular synthetic model and the varied parameter (noise, W1, or decoy), as described
in Sec. 5.1.
The first set of columns corresponds to model L. We report that most of the tests have
the same statistical power for the detection of the significant covariate X1 for this model. As
expected, the linear test MoLin performs very well, similarly to tests which are sensitive to a
global measurements on the cumulative process, such as AreaB and SAreaB, since averaging
over the whole curve provides more robustness. The MaxBE test does not perform well on
linear data, as it is designed to capture transient correlations. Because of this feature, for L,
it mostly detects unrelated fluctuations. The combined test Comb is also shown to perform
very well in the linear setting.
The next four sets of columns correspond to the piecewise constant models (PC) and
their associated experimental axes. For this class of models, the tests under study perform
very differently, revealing the strengths of each individual test, which we now describe.
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i) Threshold detection. As expected, MaxB performs the best for detection of threshold
effects, at least when threshold is centrally located (PC-Th1). Actually, this task appears
relatively easy since most tests report good power, even MoLin. However, when the threshold
is closer to the boundaries, and therefore more difficult to detect as in PC-Th2, the MaxB
test fails to recognize the significant covariate, as do most of the other tests. However,
MaxBN performs very well in this setting due to the normalization hull which brings more
power to the extreme sides of.
ii) Interval detection. This task appears to be very difficult for most tests, which fail
catastrophically on both PC-Int1 and PC-Int2. The MaxB and MaxBN tests can only
detect a single jump discontinuity, while AreaB, SAreaB, and MoLin are global measures
which are unable to capture such a localized phenomenon. The only two tests which give
strong positive results on this task is the MaxBE test and its normalized version MaxBEN ,
since large excursions of the cumulative process correspond to a transient effect on the
covariates.
We also see that Comb demonstrates very robust behavior across all the tested models and
experimental parameters. While it does not always provide the best possible performance,
its strength lies in its ability to operate in widely varied settings, from global linear trends
to narrow threshold or interval effects.
Finally, to see how those tests would perform on less artificial models, the next set
of columns correspond to experiments performed on the NL model. Here, we report the
detection performance for each of the significant variables in NL. Once again, we observe
that particular experimental configurations of this model can lead to individual test failures.
However, once again we see that Comb demonstrates very robust performance across all
tested experimental parameters.
These synthetic experiments have illustrated the ability of each individual test to detect
known significant covariates under specific assumptions. When those assumptions are known
a priori by the investigator (e.g. a known threshold effect), then it may be wiser to select the
individual test according to this knowledge. However, when this knowledge is not available
or too uncertain, our analysis suggests that Comb could be a robust solution. We present
our full set of results both in terms of normalized AUC as well as raw statistical power in
Appendix B.
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Figure 5: Visual representation of results obtained from all proposed statistical tests, along
with the baseline MoLin, when performed over the synthetic treatment-interaction models
(L, PC, and NL) described in Sec. 5. Evaluated significance tests are given as rows while
synthetic models and the experimentation parameter are given as columns. Colors are used
to indicate different synthetic models. Presented performance scores are given as the nor-
malized area under the curve over the tested experimental parameter (noise, W1, decoy).
Normalization is performed over the significance tests such that the best-performing test
reports a performance score of 1. The final two columns represent the aggregate minimum
and average performance of each significance test over the set of tested models and experi-
mentation parameters. Each significance is shown to perform well on some models but worse
on others. Notably, the combined test (Comb, last row), shows robust performance across
all experiments.
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6 Exploration on Real Trials
We now turn our attention to the utility of our new individual tests and their combination
in a more realistic setting. In this section, we describe results of application of our method
to several real world clinical trial datasets. For these datasets, there are no known ground
truths for significant covariates. However, as we control Type-I error, we can deduce that
detecting more significant covariates is a desirable property for a successful statistical test
on these real datasets.
6.1 CALGB 40603 (NCT00861705)
The primary objective of this study was to investigate whether adding bevacizumab to
paclitaxel (+/- carboplatin) and subsequent dose-dense doxorubicin and cyclophosphamide
(ddAC) significantly raises the rate of pathologic complete response (pCR) in the breast of
patients with HR-poor/ HER2(-), resectable breast cancer [25]. The patient level data of this
study can be retrieved from Project DataSphere1 [26]. The dataset contains the information
on 443 patients randomly assigned to four different arms,
1. paclitaxel → ddAC,
2. paclitaxel + bevacizumab → ddAC + bevacizumab,
3. paclitaxel + carboplatin → ddAC,
4. paclitaxel + carboplatin + bevacizumab → ddAC + bevacizumab.
The dataset contains 45 covariates that can be used to explain the treatment effect when
comparing the 4 arms.
Table 2 provides the number of significant variables (0.05 p-value significance threshold
after Bonferoni correction) detected by the various tests when comparing Arm 1 versus 2, 1
versus 3, etc. For example, there two significant interactions when we compare Arms 2 and 4,
the clinical N-stage (characterization of the regional lymph node involvement) and clinical
T-stage (characterization of the size and extent of the tumor). We see that these covariates
are detected only by the combined test, meaning that the application of individual test
1https://www.projectdatasphere.org/projectdatasphere/html/content/162
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would not have been sufficient for the detection of this interaction. A similar phenomenon
is observed when we analyze the results of the comparison of Arms 3 and 4. Two significant
descriptors are detected: clinical N-stage and number of sentinel nodes examined.
Again, only the combined test was capable of detecting both interactions simultaneously.
Fig. 6 shows examples of the cumulative curves corresponding to significant variables for the
comparison of Arms 3 and 4.
Figure 6: CALGB 40603 dataset, Arm 4 versus Arm 3. Cumulative processes generated
from true covariate data (red) is contrasted with those constructed from random patient
permutations (blue). Left: Evaluation of the clinical N-stage covariate. Right: Evaluation
of the number of sentinal nodes examined covariate.
In both cases, the impact is negative, meaning that smaller covariate values correspond
to larger differences between treatment and placebo (or reference treatment) arms, therefore
implying that patients with smaller values of these covariates are more likely to benefit from
the administration of bevacizumab. Since each of the detected covariates characterize the
complexity of the tumor, the discovered dependencies suggest that patients at early stages
of the disease are more likely to benefit from the addition of bevacizumab.
6.2 BCRP
The objective of this study was to compare the impact of nutritional and educational inter-
ventions on the psychological and physical adjustment after treatment for early-stage breast
cancer [27]. The dataset was retrieved from the Quint package [28]. In total, there are 252
patients split into three arms: Arm 1: nutrition intervention (N = 85), Arm 2: educational
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intervention (N = 83), Arm 3: standard care (N = 84). Similar to the CALGB results,
as shown in Table 2, the combined test was the most sensitive test (0.05 p-value threshold
after Bonferoni correction), indicating that the nationality covariate is a significant factor
in determining the physical functioning score (SF36).
6.3 ACOSOG Z6051 (NCT00726622)
This is a randomized Phase-III trial evaluating the safety and efficacy of laparoscopic re-
section for rectal cancer [29]. The 462 patients were split into two groups: Arm 1 (open
rectal resection) and Arm 2 (laparoscopic rectal resection). Among all tests, as shown in Ta-
ble 2, the combined test and extermal of the normalized Brownian Bridge test were capable
of detecting one covariate significantly correlated with the efficacy of the treatment regime
(0.05 p-value significance threshold after Bonferoni correction): distance to nearest radial
margin. The cumulative process corresponding to this variable is shown in Fig. 7, where
patients with lower values of the distance to nearest radial margin covariate are shown to be
more likely to benefit more from the laparoscopic rectal resection. The distance to nearest
radial margin variable is not a parameter that can be assessed prior to the intervention,
it is a characteristic that can be measured once the operation is complete. Therefore, it can
not be used to guide the selection of the intervention type. However, such post-treatment
dependencies can provide useful insights into the circumstances where a treatment of interest
may prove most efficient.
Figure 7: ACOSOG Z6051 dataset evaluated for the distance to nearest radial margin
covariate. Cumulative processes generated from true covariate data (red) is contrasted with
those constructed from random patient permutations (blue).
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CALGB BCRP (C) BCRP (P) ACOSOG
Test 1v2 1v3 1v4 2v4 3v4 1v3 2v3 1v3 2v3 1v2 Total
MoLin 0 0 0 0 0 0 0 0 0 0 0
Max 0 0 0 0 0 0 0 0 0 0 1
MaxBN 1 0 1 0 1 0 0 0 0 1 4
MaxBE 0 0 0 0 0 0 0 0 0 0 0
AreaB 0 0 0 0 1 0 0 0 0 0 1
SAreaB 0 0 0 0 1 0 0 0 0 0 1
Comb 1 0 2 2 2 0 0 0 1 1 9
Table 2: Number of significant features detected by various statistical tests in CALGB
40603, BCRP and ACOSOG Z6051 studies. BCRP (C) and (P) correspond to two different
endpoints defined in the study: CESD score and SF36 scores. Each row corresponds to a
particular test. See Table 1 for test name abbreviations. Columns names “AvB” describe
comparisons between different arms of the study; see text for a more detail descriptions
of study arms. The last column (Total) reports the total number of significant variables
detected by each test across all evaluated studies.
7 Discussion
In this paper, we presented a series of new statistical tests tailored for the detection of com-
plex, non-linear treatment-covariate dependencies in clinical trial datasets. We describe how
to merge these tests into a single combined test capable of efficiently detecting different types
of interactions. We illustrated the performance of the proposed approach on various syn-
thetic models, where we compare it to existing approaches. We also describe an application
of the proposed procedure to three real world clinical trial datasets where we observed that
our proposed tests do indeed allow one to detect signals which can go undiscovered using
existing approaches.
The proposed technique is a univariate procedure tailored for the detection of single
biomarkers, and therefore is relatively easy to interpret with respect to multivariate ap-
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proaches. However, this characteristics is also a significant limitation of the procedure since,
as with any univariate approach, one needs to apply multiple testing correction (e.g. Bon-
feroni) to account for the number of covariates analyzed. In some cases, this correction
might be too drastic. This issue can be partially resolved by imposing a pre-order on the
list of covariates defined by an expert or by automatically extracting an ordering from the
literature or an external dataset. Another consequence of the nature of univariate tests is
that such a test can miss complex dependencies involving multiple covariates if each of them
separately do not present statistically significant signals.
In our future research, we plan generalize our proposed cumulative tests to a multivariate
setting, and explore the possibility of building a statistical test capable of detecting non-
linear multivariate dependencies with a proper control over Type-I error. Another interesting
direction is the incorporation of external data sources as prior knowledge. By continuing to
analyze publicly available clinical trial datasets, we hope to find new and interesting covariate
dependencies, as well as to construct a large benchmark of datasets for the comparison of
covariate-detection methods.
In this article, we focused on the detection of covariates interacting with the treatment
efficacy. Such covariates provide a natural basis for sub-group selection. The extension of
the proposed statistical tests for sub-group identification is another important direction that
we hope to address in our future work.
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A Outcome Centering Proofs
A.1 Proof of Lemma 1
As stated in the lemma, we assume that a “general” modified outcome written in the form
Ŷ = T · (R + f(T )), where f(T ) is an arbitrary function of T . Looking at the variance of
this general modified outcome we have
var[Ŷ ] = var [T · (R + f(T ))] . (29)
Using the law of total variation, we next condition on the treatment, T ,
var[Ŷ ] =E [varR [T · (R + f(T ))|T ]]
+ var [ER [T · (R + f(T ))|T ]] . (30)
The conditional variance can be written as
varR [T · (R + f(T ))|T ] = T 2 · var [R|T ] , (31)
which follows from the application of the translational invariance property as well as the
scaling identity. Subsequently, for the conditional expectation, we find
ER [T · (R + f(T ))|T ]
= ER [T ·R|T ] + ER [T · f(T )|T ]
= T · (E [R|T ] + f(T )), (32)
which follows from both the linearity of expectation as well as the independence of T from
R. Taken together, we have
var[Ŷ ] = E
[
T 2 · var[R|T ]]
+ var[T · (E[R|T ] + f(T ))]. (33)
From the above, we see that the only a variance term is dependent upon the choice of
f(T ). Since the variance must not be negative, the minimum variance σ∗ = E[T 2 ·var[R|T ]]
is obtained when var [T · (E[R|T ] + f(T ))] = 0. It can be directly observed that f(T ) =
−E[R|T ] is one such choice of f(T ) for which var[Ŷ ] = σ∗.
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A.2 Proof of Lemma 2
We first calculate the variance of the modified outcome as presented in [8]. Recalling Ymod =
T ·R, we see
var[Ymod] = var[R · T ],
= E[varR[T ·R|T ]] + var[ER[T ·R|T ]],
= E[T 2 · var[R|T ]] + var[T · E[R|T ]]. (34)
which follows first from the law of total variation, and also from our earlier calculations in
Appendix A.1.
We now make the calculation of this variance explicit through the empirical per-trial first
and second moments, µT and σ
2
T , respectively. For the first term,
E[T 2 · var[R|T ]]
=
∑
t∈{±1}
pit · t2 · var[R|T = t],
=
1
2
· (σ21 + σ2−1)2. (35)
Subsequently,
var[T · E[R|T ]]
= E[(T · E[R|T ])2]− E2[T · E[R|T ]],
=
∑
t∈{±1}
pit · t2 · E2[R|T = t]
−
 ∑
t∈{±1}
pit · t · E[R|T = t]
2 ,
=
1
4
(µ1 − µ−1)2. (36)
Finally, we have
var[Ymod] =
1
2
(σ21 + σ
2
−1) +
1
4
(µ1 − µ−1)2. (37)
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In contrast, we have the value of the modified outcome with per-treatment centering, as
shown in Lemma 1,
var[Y˜ ] = E[T 2 · var[R|T ]],
=
1
2
(σ21 + σ
2
−1). (38)
Thus, for the ratio γ = var[Y˜ ]
var[Ymod]
,
γ =
1
2
(σ21 + σ
2
−1)
1
2
(σ21 + σ
2
−1) +
1
4
(µ1 − µ−1)2 ,
=
1
1 + 1
2
· (µ1−µ−1)2
σ21+σ
2
−1
,
= 1− sig
[
log
(µ1 − µ−1)2
σ21 + σ
2
−1
− log 2
]
. (39)
where sig(x) = 1
1+e−x is the logistic sigmoid function. Since sig(x) is bounded in range [0, 1]
over the domain x ∈ R, we can see that γ ∈ [0, 1], as well. Additionally, we see directly
that the only instance in which γ = 1 is the case that µ1 = µ−1, that is, when the measured
responses for both treatments have the same expectation.
A.3 Proof of Lemma 3
The conditional covariance of the centered outcome can be shown to be
cov[R˜, T |X]
= cov [R− E[R|T ], T |X] ,
= cov[R, T |X]− cov[E[R|T ], T |X],
= cov[R, T |X]− E[T · E[R|T ]|X],
+ E[E[R|T ]|X] · E[T |X]. (40)
Assuming a properly randomized trial such that T ⊥ X and centered treatment variables,
E[T ] = 0, then the covariance becomes
cov[R˜, T |X]
= cov[R, T |X]− E[T · E[R|T ]|X]. (41)
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However, since T ⊥ X and the measured outcome R is a fixed property of the dataset
which does not change based on the covariate selection X, we note that E[T · E[R|T ]|X] =
E[T · E[R|T ]]. Thus, the second term is constant with respect to the covariate under test
and we write it as CR,T .
A.4 Proof of Lemma 4
The unconditioned covariance between the centered treatment response and the treatment
indicators is
cov[R˜, T ]
= cov[R− E[R|T ], T ],
= cov[R, T ]− cov[E[R|T ], T ], (42)
which follows from the simple distributional property of the covariance. Since we assume cen-
tered treatment indicator variables, E[T ] = 0, this difference in covariances can be simplified
to the difference,
cov[R˜, T ] = E[T ·R]− E[T · E[R|T ]]. (43)
However, we can see that these two terms are equivalent. Using the total expectation, we
observe that E[T · R] = ET [ER[T · R|T ]], where we use subscripts to make the expectations
explicit. Moving the constant T outside of the conditional expectation, we have E[T · R] =
E[T · E[R|T ]], which shows the equivalence of the two terms. Thus, cov[R˜, T ] = 0.
38
B Full Synthetic Results
Synthetic Model MoLin AreaB SAreaB MaxB MaxBN MaxBE MaxBEN Comb
L
Base (W1) 0.958 0.979 0.990 0.896 0.896 0.604 0.396 0.990 (0.0%)
Treatment (W2) 0.969 0.948 0.927 0.885 0.854 0.510 0.250 0.896 (-7.5%)
Noise 0.865 0.865 0.875 0.792 0.771 0.490 0.177 0.833 (-4.8%)
Decoy 0.667 0.719 0.677 0.531 0.469 0.094 0.031 0.562 (-21.8%)
PC-Int2
Noise 0.042 0.042 0.052 0.188 0.104 0.427 0.219 0.375 (-12.2%)
Decoy 0.000 0.000 0.000 0.010 0.000 0.010 0.000 0.000 (-100.0%)
Base (W1) 0.021 0.010 0.031 0.083 0.042 0.177 0.083 0.125 (-29.4%)
PC-Th1
Noise 0.531 0.562 0.573 0.635 0.833 0.417 0.562 0.823 (-1.2%)
Decoy 0.021 0.021 0.042 0.021 0.062 0.031 0.042 0.052 (-16.1%)
Base (W1) 0.198 0.188 0.188 0.104 0.333 0.073 0.177 0.292 (-12.3%)
PC-Int1
Noise 0.688 0.719 0.719 0.729 0.635 0.583 0.219 0.750 (2.9%)
Decoy 0.292 0.292 0.302 0.354 0.292 0.177 0.010 0.240 (-32.2%)
Base (W1) 0.802 0.802 0.823 0.844 0.677 0.667 0.312 0.698 (-17.3%)
PC-Th2
Noise 0.010 0.219 0.260 0.375 0.427 0.781 0.688 0.771 (-1.3%)
Decoy 0.000 0.000 0.000 0.021 0.010 0.229 0.156 0.094 (-59.0%)
Base (W1) 0.042 0.219 0.229 0.312 0.365 0.688 0.646 0.500 (-27.3%)
NL
Noise: X7, X8 0.026 0.042 0.068 0.083 0.120 0.203 0.203 0.161 (-20.7%)
Noise: X6 0.281 0.271 0.260 0.219 0.260 0.104 0.052 0.375 (33.5%)
Noise: X5 1.000 1.000 1.000 0.990 0.969 0.698 0.312 1.000 (0.0%)
Noise: X3 0.062 0.146 0.135 0.135 0.292 0.562 0.615 0.479 (-22.1%)
Noise: X1 0.323 0.302 0.302 0.302 0.292 0.115 0.083 0.365 (13.0%)
Decoy: X7, X8 0.000 0.000 0.000 0.000 0.005 0.031 0.042 0.005 (-88.1%)
Decoy: X6 0.073 0.083 0.083 0.031 0.010 0.010 0.000 0.073 (-12.0%)
Decoy: X5 0.979 0.979 0.990 0.938 0.927 0.688 0.167 0.969 (-2.1%)
Decoy: X3 0.010 0.010 0.010 0.031 0.125 0.302 0.385 0.229 (-40.5%)
Decoy: X1 0.104 0.115 0.115 0.052 0.052 0.000 0.000 0.083 (-27.8%)
Table B1: Full table of raw statistical power for synthetic tests.
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Synthetic Model MoLin AreaB SAreaB MaxB MaxBN MaxBE MaxBEN Comb
L
Base (W1) 0.994 0.998 1.000 0.969 0.965 0.880 0.697 0.999 (-0.1%)
Treatment (W2) 1.000 0.990 0.980 0.953 0.938 0.753 0.618 0.967 (-3.3%)
Noise 0.978 0.975 0.982 0.950 0.925 0.750 0.455 0.976 (-0.6%)
Decoy 0.991 1.000 0.993 0.947 0.873 0.551 0.158 0.925 (-7.5%)
PC-Int2
Noise 0.120 0.347 0.433 0.578 0.485 0.839 0.578 0.838 (-0.1%)
Decoy 0.034 0.037 0.060 0.135 0.102 0.250 0.165 0.077 (-69.2%)
Base (W1) 0.062 0.081 0.103 0.190 0.150 0.349 0.221 0.234 (-33.0%)
PC-Th1
Noise 0.632 0.652 0.657 0.665 0.849 0.547 0.652 0.883 (4.0%)
Decoy 0.225 0.261 0.262 0.256 0.570 0.209 0.321 0.286 (-49.8%)
Base (W1) 0.517 0.493 0.517 0.350 0.762 0.303 0.500 0.599 (-21.4%)
PC-Int1
Noise 0.899 0.914 0.917 0.940 0.860 0.812 0.592 0.921 (-2.0%)
Decoy 0.861 0.883 0.940 0.954 0.790 0.636 0.271 0.865 (-9.3%)
Base (W1) 0.936 0.956 0.983 1.000 0.857 0.807 0.405 0.919 (-8.1%)
PC-Th2
Noise 0.043 0.588 0.638 0.699 0.740 0.946 0.902 0.959 (1.4%)
Decoy 0.031 0.135 0.173 0.286 0.377 0.990 0.797 0.705 (-28.8%)
Base (W1) 0.089 0.302 0.323 0.445 0.516 1.000 0.880 0.710 (-29.0%)
NL
Noise: X7, X8 0.130 0.400 0.431 0.461 0.692 0.920 0.990 0.890 (-10.1%)
Noise: X6 0.954 0.956 0.951 0.889 0.822 0.569 0.207 0.900 (-5.9%)
Noise: X5 0.999 1.000 1.000 0.996 0.993 0.914 0.689 0.996 (-0.4%)
Noise: X3 0.062 0.580 0.591 0.578 0.783 0.931 1.000 0.917 (-8.3%)
Noise: X1 0.935 0.921 0.907 0.813 0.906 0.287 0.099 0.914 (-2.2%)
Decoy: X7, X8 0.033 0.052 0.074 0.104 0.221 0.352 0.448 0.276 (-38.4%)
Decoy: X6 0.720 0.729 0.730 0.639 0.510 0.297 0.113 0.647 (-11.4%)
Decoy: X5 1.000 1.000 1.000 0.998 0.996 0.911 0.400 0.997 (-0.3%)
Decoy: X3 0.029 0.235 0.264 0.270 0.576 0.833 0.987 0.726 (-26.4%)
Decoy: X1 0.720 0.696 0.616 0.500 0.611 0.088 0.053 0.630 (-12.5%)
Table B2: Full table of normalized area for synthetic tests.
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